Similarly, capecitabine, the chemotherapeutic agent, combined with inetetamab also resulted in potent tumor regression comparable to that of inetetamab plus lapatinib by day 25 posttreatment (Figure 4a and b), suggesting that regardless of antitumor mechanism, with one inhibiting the cell cycle and the other targeting growth signaling pathways, the two agents exhibited synergistic antitumor effects similar to those of anti-HER2 mAb therapy in the treatment of NCI-N87 tumors. This evidence concerns the gene ERBB2 and neoplasm.